HiberCell is advancing novel therapeutics that target adaptive stress pathways. Treatment resistance, cancer relapse and metastasis are unfortunate outcomes for cancer patients. By targeting the induction of adaptive stress, a common feature of these outcomes, HiberCell is pioneering a new cancer treatment paradigm. With this strategy, HiberCel has developed a differentiated pipeline of therapy candidates: this includes HC-5404, a differentiated, orally bioavailable investigational small molecule inhibitor of PERK, a kinase of the unfolded protein response. As preclinical models show PERK activation in response to various cancer therapies, HiberCell is looking to test the therapy for advanced solid tumors.

HiberCell

Founded: 2019
Location: New York, NY
Employee range: 50 - 200
Clinical stage: Clin2
Therapy area: liver metastasis, pancreatic cancer
Drug types: ONC
Lead product: Odetiglucan
Funding: $67.4M B May 2021; $61M A Feb 2019

Drug notes:

About:

Jobs: